AGENUS INC Interest Expense Nonoperating
AGENUS INC (AGEN) reported Interest Expense Nonoperating of $15.36 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Expense Statement
us-gaap:InterestExpenseNonoperating · last filed 2026-08-07
- AGENUS INC interest expense nonoperating for the quarter ending 2026-06-30 was $15.36M, a 15.14% increase year-over-year.
- AGENUS INC interest expense nonoperating for the quarter ending 2026-03-31 was $14.69M, a 13.15% increase year-over-year.
- AGENUS INC interest expense nonoperating for the quarter ending 2025-12-31 was $16.05M, a 23.99% decline year-over-year.
- AGENUS INC interest expense nonoperating for the quarter ending 2025-09-30 was $13.24M, a 63.96% decline year-over-year.
- AGENUS INC interest expense nonoperating for fiscal 2025 was $55.62M, a 53.81% decline from fiscal 2024.
- AGENUS INC interest expense nonoperating for fiscal 2024 was $120.42M, a 15.95% increase from fiscal 2023.
- AGENUS INC interest expense nonoperating for fiscal 2023 was $103.86M, a 61.98% increase from fiscal 2022.
- AGENUS INC interest expense nonoperating for fiscal 2022 was $64.12M.
| Period end | Interest Expense Nonoperating 3 month | Interest Expense Nonoperating 6 month | Interest Expense Nonoperating 9 month | Interest Expense Nonoperating 12 month |
|---|---|---|---|---|
| 2026-06-30 | $15.36M 10-Q · filed 2026-08-07 | $30.05M 10-Q · filed 2026-08-07 | $46.10M derived: sum of 3 quarters · filed 2026-08-07 | $59.35M derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | $14.69M 10-Q · filed 2026-05-11 | $30.74M derived: sum of 2 quarters · filed 2026-05-11 | $43.98M derived: sum of 3 quarters · filed 2026-05-11 | $57.33M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | $16.05M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $29.29M derived: sum of 2 quarters · filed 2026-03-16 | $42.64M derived: sum of 3 quarters · filed 2026-08-07 | $55.62M 10-K · filed 2026-03-16 |
| 2025-09-30 | $13.24M 10-Q · filed 2025-11-10 | $26.59M derived: sum of 2 quarters · filed 2026-08-07 | $39.57M 10-Q · filed 2025-11-10 | $60.69M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-06-30 | $13.34M 10-Q · filed 2026-08-07 | $26.32M 10-Q · filed 2026-08-07 | $47.44M derived: sum of 3 quarters · filed 2026-08-07 | $84.19M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | $12.98M 10-Q · filed 2026-05-11 | $34.10M derived: sum of 2 quarters · filed 2026-05-11 | $70.85M derived: sum of 3 quarters · filed 2026-05-11 | $103.13M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $21.11M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $57.86M derived: sum of 2 quarters · filed 2026-03-16 | $90.15M derived: sum of 3 quarters · filed 2026-03-16 | $120.42M 10-K · filed 2026-03-16 |
| 2024-09-30 | $36.75M 10-Q · filed 2025-11-10 | $69.03M derived: sum of 2 quarters · filed 2025-11-10 | $99.31M 10-Q · filed 2025-11-10 | |
| 2024-06-30 | $32.28M 10-Q · filed 2025-08-11 | $62.56M 10-Q · filed 2025-08-11 | ||
| 2024-03-31 | $30.27M 10-Q · filed 2025-05-12 | |||
| 2023-12-31 | $103.86M 10-K · filed 2026-03-16 | |||
| 2022-12-31 | $64.12M 10-K · filed 2025-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |